Patch International

Patch Biosciences is a biotechnology company that leverages an AI-driven platform for the sequence design of genetic medicines. The company specializes in engineering synthetic promoters and untranslated regions (UTRs) to enhance the effectiveness, specificity, and durability of gene and cell therapies. By integrating machine learning models with downstream biological assays, Patch Biosciences aims to optimize the expression of therapeutic payloads across various modalities, including AAV-based gene therapies and RNA therapeutics. In February 2024, the company was acquired by Ginkgo Bioworks to bolster its genetic medicine services and circular RNA screening capabilities.